Recent developments with Abbott Laboratories (ABT) have led to the company’s beta value being reach 0.72 cents.

Abbott Laboratories (NYSE: ABT) on Friday, soared 0.22% from the previous trading day, before settling in for the closing price of $103.45. Within the past 52 weeks, ABT’s price has moved between $89.67 and $121.64.

Annual sales at Healthcare sector company grew by 6.10% over the past five years. The company achieved an average annual earnings per share of 4.25%. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.73 billion.

Let’s look at the performance matrix of the company that is accounted for 114000 employees.

Abbott Laboratories (ABT) Insider and Institutional Ownership

Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Abbott Laboratories is 0.72%, while institutional ownership is 77.16%. The most recent insider transaction that took place on May 10 ’24, was worth 1,055,819. In this transaction EXECUTIVE VICE PRESIDENT of this company sold 10,097 shares at a rate of $104.57, taking the stock ownership to the 211,341 shares. Before that another transaction happened on May 07 ’24, when Company’s EXECUTIVE VICE PRESIDENT sold 22,852 for $106.25, making the entire transaction worth $2,428,119. This insider now owns 61,462 shares in total.

Abbott Laboratories (ABT) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 4.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.10% during the next five years compared to 19.65% growth over the previous five years of trading.

Abbott Laboratories (NYSE: ABT) Trading Performance Indicators

Abbott Laboratories (ABT) is currently performing well based on its current performance indicators. A quick ratio of 1.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.47. Likewise, its price to free cash flow for the trailing twelve months is 36.64.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.21, a number that is poised to hit 1.11 in the next quarter and is forecasted to reach 5.14 in one year’s time.

Technical Analysis of Abbott Laboratories (ABT)

Abbott Laboratories (NYSE: ABT) saw its 5-day average volume 5.81 million, a positive change from its year-to-date volume of 5.67 million. As of the previous 9 days, the stock’s Stochastic %D was 28.45%. Additionally, its Average True Range was 1.74.

During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 14.48%, which indicates a significant decrease from 36.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 20.41% in the past 14 days, which was higher than the 18.03% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $105.80, while its 200-day Moving Average is $106.16. Nevertheless, the first resistance level for the watch stands at $104.12 in the near term. At $104.57, the stock is likely to face the second major resistance level. The third major resistance level sits at $105.41. If the price goes on to break the first support level at $102.83, it is likely to go to the next support level at $101.99. The third support level lies at $101.54 if the price breaches the second support level.

Abbott Laboratories (NYSE: ABT) Key Stats

Market capitalization of the company is 180.36 billion based on 1,739,634K outstanding shares. Right now, sales total 40,109 M and income totals 5,723 M. The company made 9,964 M in profit during its latest quarter, and 1,225 M in sales during its previous quarter.